title: Beyond approval: what is the most appropriate way to use the expanding Armamentarium in metastatic castration-resistant prostate cancer and how do we move forward?
authors.affiliation: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore MD, USA.
authors.forename: Daniel
authors.initials: D
authors.lastname: Suzman
authors.affiliation: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore MD, USA. Electronic address: eisenma@jhmi.edu.
authors.forename: Mario
authors.initials: M
authors.lastname: Eisenberger
mesh_terms: D000069501:Abiraterone Acetate; D000736:Androstenes / Q000008:administration & dosage*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D065607:Cytochrome P-450 Enzyme Inhibitors / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*; D013254:Steroid 17-alpha-Hydroxylase / Q000037:antagonists & inhibitors*
chemical_list: D000736:Androstenes; D018931:Antineoplastic Agents, Hormonal; D065607:Cytochrome P-450 Enzyme Inhibitors; D013254:Steroid 17-alpha-Hydroxylase; D000069501:Abiraterone Acetate